Health & Biotech
Race Oncology (ASX: RAC) is an ASX-listed clinical stage, global biotechnology company with a dedicated mission to be at the heart of cancer care. Race’s lead asset, bisantrene, is a small molecule anthracene chemotherapeutic. Bisantrene has a unique and rich clinical history with demonstrated therapeutic benefits in both adult and paediatric patients, as well characterised safety profile, and compelling clinical data demonstrating an anti-cancer effect and a lack of cardiotoxicity.
Race is developing bisantrene to address the high unmet need of patients across multiple oncology indications, with an initial focus on metastatic breast cancer (lead indication) and acute myeloid leukaemia (AML), exploring anti-cancer plus cardio-protection in synergy with known standards of care.
As part of its clinical program, Race is also investigating the impact bisantrene and new molecules have on the m6A RNA pathway, following independent research describing bisantrene as the most potent inhibitor of FTO (Fat mass and obesity-associated protein). Dysregulation of RNA (over expression of FTO) has been shown to be a driver of a diverse range of cancers.
Race Oncology is in collaboration with City of Hope, MD Anderson, Sheba City of Health and UNC School of Medicine, and is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to bisantrene for patients with cancer across the world. Learn more at www.raceoncology.com
KEY PEOPLE
RELATED STOCKHEAD STORIES
News
Closing Bell: ASX finishes flat
Stockhead TV
V-Con: Talking medical innovations and breakthrough treatments with ASX biotechs
Health & Biotech
Suda Pharma pops 44pc on cap raise; Acrux and other biotechs whet investor appetites
News
Last Orders: ASX rebounds after yesterday’s sharp drop
Health & Biotech
‘Miracle’ breakthrough in melanoma fight puts focus on ASX stocks in the skin cancer space
News
Last Orders: ASX rebounds 1 per cent after yesterday’s plunge
Experts
ScoPo’s Powerplays: Health sector trades sideways but M&A plays coloured the week
News
Last Orders: ASX edges further towards pre-pandemic record high
Experts
ScoPo’s powerplays: His Mach7 pick paid off – will Impedimed rise as well?
Experts
ScoPo’s powerplays: It’s been a rollercoaster ride, but take a look at Neuren
Health & Biotech
Check Up: Most health stocks have been feeling unwell, but Singular Health has tripled from IPO price
Health & Biotech
Orphan Drug Designation: Here’s why it’s a big deal for small cap biotechs
Health & Biotech
Blood cancer is becoming a big killer but there are only a handful of ASX stocks fighting it
Health & Biotech
Clinical Trials Tracker: 2022 and beyond
News
Weekly ASX small cap wrap: Who’s on the hunt for a Black Friday bargain this week?
Health & Biotech
Race Oncology, Analytica shares rise after results; Race up 3,500pc in 16 months
News